A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.

Main|Search|PHGKB




Last Posted: Dec 13, 2018

---

• A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
  Velázquez Carolina et al. Breast (Edinburgh, Scotland) 2018 Nov 4391-96
• Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers A Complex Discussion
  S Domchek, JAMA< December 6, 2018
• A Proposed Approach for Implementing Genomics-Based Screening Programs for Healthy Adults
  M. Murray and the Genomics and Population Health Action Collaborative, National Academies of Medicine, December 3, 2018
• Uterine cancer in Jewish Israeli BRCA1/BRCA2 mutation carriers.
  Laitman Yael et al. Cancer 2018 Nov
• Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
  Frey Melissa K et al. Cancer 2018 Nov
• Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
  Singer Christian F et al. European journal of cancer (Oxford, England : 1990) 2018 Nov 10654-60
• No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer.
  Jacobson Michelle et al. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2018 Nov 40(11) 1497-1510
• Risk Reduction and Survival Benefit of Risk-Reducing Salpingo-oophorectomy in Hereditary Breast Cancer: Meta-analysis and Systematic Review.
  Xiao Ye-Lei et al. Clinical breast cancer 2018 Oct
• A Recurrent BRCA2 Mutation Explains the Majority of Hereditary Breast and Ovarian Cancer Syndrome Cases in Puerto Rico.
  Diaz-Zabala Hector J et al. Cancers 2018 Nov 10(11)
• Population Based Testing for Primary Prevention: A Systematic Review.
  Manchanda Ranjit et al. Cancers 2018 Nov 10(11)

more